260660 — Korea Arlico Pharm Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMicro CapNeutral

Annual income statement for Korea Arlico Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	ARS	Annual Audited Accounts
Standards:	IFRS	IFRS	—	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	115,793	124,809	140,157	167,737	187,155
Cost of Revenue
Gross Profit	73,470	79,808	87,529	106,924	110,179
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	103,229	114,210	135,363	157,873	184,082
Operating Profit	12,564	10,599	4,794	9,864	3,073
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	12,151	9,728	5,605	8,391	3,476
Provision for Income Taxes
Net Income After Taxes	10,031	8,372	4,930	8,034	3,061
Net Income Before Extraordinary Items
Net Income	10,031	8,372	4,930	8,034	3,061
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	10,031	8,372	4,930	8,720	1,755
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	665	566	271	550	104
Dividends per Share